BioDiem buys Savine Therapeutics

By Dylan Bushell-Embling
Thursday, 15 December, 2011

Melbourne-based vaccine developer company BioDiem (ASX:BDM) has acquired Savine Therapeutics, and the company's antigen technology.

Savine Therapeutics was founded in 2007 to commercialise its Scrambled Anigen Vaccine (Savine) IP, which it acquired from the Australian National University.

Savine is used to design antigens to be used in vaccines. The antigens are ‘scrambled,’ or re-engineered from key proteins, to retain immunologically-relevant characteristics while removing dangerous functions.

The technology was jointly invented by BioDiem's current scientific consultant, Dr Scott Thomspon.

The acquisition includes the Savine technology, the software used to design the antigens and a number of Savine-manufactured genes.

Terms of the transaction were not disclosed, but an ASX filing shows that BioDiem has allocated 111,111 ordinary shares in part payment.

Biodiem CEO Julie Phillips said the company viewed Savine's technology as “highly complementary” to its own IP.

“In our vaccine business the key elements are a virus, a cell line to grow the virus, and antigens,” Phillips said.

“BioDiem now has all of these components through the Live Attenuated Influenza Virus, the mammalian cell line recently licensed and now the acquisition of the Savine antigen technology.”

As well as using Savine internally, BioDiem will also be able to license the technology to third parties, she added.

BioDiem (ASX:BDM) shares stayed flat during Wednesday's trading at $0.084.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd